Equity Profile

SYRE

Spyre Therapeutics, Inc.

Health CareBiotechnology$8.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and performance this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercial success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs and improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q1-2026, Spyre Therapeutics reported an EPS of -$0.74, missing estimates by 11.45%. Despite the miss, the stock rose 2.72% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, especially given the mixed performance in previous quarters. The focus will be on whether the company can show signs of improvement in profitability and revenue.

Bull Case

If Spyre can demonstrate progress in its clinical trials and show better-than-expected revenue growth, it could lead to a positive reassessment of its future prospects.

Bear Case

Conversely, if the company continues to report losses and fails to provide clear guidance on its clinical programs, it may lead to further declines in investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials are crucial as they can directly impact the company's future revenue potential and market position.

Can the company provide guidance on revenue expectations for the next quarter?

Clear revenue guidance is essential for setting investor expectations and assessing the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial advancements, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing in a 9.38% move, indicating expectations of volatility that may not align with the company's actual performance.

Spyre's recent stock movements suggest a level of investor optimism that is not reflected in analyst estimates.

Key Risk

If clinical trial results show significant progress, it could lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could either reinforce confidence in Spyre's growth strategy or raise concerns about its financial sustainability.

Bull Confirmed If

A significant reduction in EPS losses, ideally moving towards breakeven or profitability.

Bear Confirmed If

Continued losses without clear progress in clinical trials or revenue growth.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations, history suggests the stock could see an average one-day move of +1.37%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the information.

Miss

Should the company miss expectations, history indicates an average one-day move of +2.20%, which could lead to a significant decline in stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials and their expected timelines.
2Management's guidance on revenue expectations for the upcoming quarter.
3Insights into cost management strategies and their impact on EPS.
4Details on partnerships or collaborations that could enhance growth prospects.
5Responses to questions regarding competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and performance this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercial success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q1-2026, Spyre Therapeutics reported an EPS of -$0.74, missing estimates by 11.45%. Despite the miss, the stock rose 2.72% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Spyre can demonstrate progress in its clinical trials and show better-than-expected revenue growth, it could lead to a positive reassessment of its future prospects.

Bear Case

Conversely, if the company continues to report losses and fails to provide clear guidance on its clinical programs, it may lead to further declines in investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials are crucial as they can directly impact the company's future revenue potential and market position.

Can the company provide guidance on revenue expectations for the next quarter?

Clear revenue guidance is essential for setting investor expectations and assessing the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial advancements, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The options market is pricing in a 9.38% move, indicating expectations of volatility that may not align with the company's actual performance.

Spyre's recent stock movements suggest a level of investor optimism that is not reflected in analyst estimates.

Key Risk

If clinical trial results show significant progress, it could lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could either reinforce confidence in Spyre's growth strategy or raise concerns about its financial sustainability.

Bull Confirmed If

A significant reduction in EPS losses, ideally moving towards breakeven or profitability.

Bear Confirmed If

Continued losses without clear progress in clinical trials or revenue growth.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations, history suggests the stock could see an average one-day move of +1.37%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the information.

Miss

Should the company miss expectations, history indicates an average one-day move of +2.20%, which could lead to a significant decline in stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials and their expected timelines.
2Management's guidance on revenue expectations for the upcoming quarter.
3Insights into cost management strategies and their impact on EPS.
4Details on partnerships or collaborations that could enhance growth prospects.
5Responses to questions regarding competitive positioning in the biotechnology sector.